Sai Life Sciences Limited IPO: Issue Price, Listing Gain and Share Price Now
Sai Life Sciences Limited listed on 18-Dec-2024 at ₹765.3 against an issue price of ₹549 , a listing gain of +39.40%. It last traded at ₹1,473.2. This page is the record of that issue and what has happened to it since — reported figures only.
Sai Life Sciences Limited IPO: listing gain and return since
| Measure | Value |
|---|---|
| Issue price | ₹549 |
| Listing price (listing-day close) | ₹765.3 |
| Listing gain | +39.40% |
| Price now | ₹1,473.2 |
| Change from issue price | +168.34% |
| Change from listing-day close | +92.50% |
The two changes above answer different questions and are routinely opposite in sign. The change from the issue price is what an allottee has made. The change from the listing-day close is what somebody who bought on the first day has made.
Sai Life Sciences Limited IPO details
| Issue term | Detail |
|---|---|
| Issue price (upper band) | ₹549 |
| Issue size | ₹3,042.62 Cr |
| Fresh issue | ₹950 Cr |
| Offer for sale | ₹2,092.62 Cr |
| Issue opened | 11-Dec-2024 |
| Issue closed | 13-Dec-2024 |
| Listed on | 18-Dec-2024 |
| Exchange | BSE, NSE |
| Segment | Mainboard |
| Lead managers | Kotak Mahindra Capital (left lead) |
How the Sai Life Sciences Limited IPO was subscribed
| Category | Subscription |
|---|---|
| QIB | 29.78x |
| NII | 4.99x |
| Retail | 1.39x |
| Total | 10.27x |
Sai Life Sciences Limited today
| Figure | Value |
|---|---|
| Market capitalisation | ₹31,241 Cr |
| Trailing P/E | 85.00x |
| Return on capital employed | 19.6% |
| Return on equity | 15.4% |
| 52-week high | ₹1,484 |
| 52-week low | ₹784 |
| Sector | Pharmaceuticals |
Fundamentals are as of the desk's last harvest and move with the market.
- Sai Life Sciences Limited — full issue page: every stored figure, with its source.
- How many IPOs still trade above their issue price, corporate-action adjusted.
- The full IPO archive: listing gains by year, sector and issue size.
Automated data digest. This page is compiled automatically from exchange filings and public aggregator data. It is a record of reported figures — it is not research, not a recommendation, and not investment advice.
Grey Market Premium (GMP) is an unofficial, unregulated price quoted outside the exchanges. It is not a forecast of the listing price and is frequently wrong.
Published by INVESTOLOGY — SEBI Registered Research Analyst INH000015297. Investments in securities markets are subject to market risk; read all offer documents carefully before investing. Registration granted by SEBI and NISM certification in no way guarantee performance or assure returns.